


International Application No. *r*CT/EP02/00991  
 International Filing Date: 31 January 2002

### Amendments to the Claims:

1. (Original) A compound of formula (I),



wherein,

$R^1$  is selected from H, halo, -CN, -CF<sub>3</sub>, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy;

$R^2$  is selected from -(CH<sub>2</sub>)<sub>n</sub>-phenyl, -(CH<sub>2</sub>)<sub>n</sub>-heterocyclyl, -(CH<sub>2</sub>)<sub>n</sub>-heteroaryl, each of which may be further substituted by one or more substituents, which may be the same or different, selected from halo (such as fluoro, chloro, bromo), -CN, -CF<sub>3</sub>, -OH, -OCF<sub>3</sub>, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy, -NO<sub>2</sub>, -NH<sub>2</sub>, -NR<sup>3</sup>R<sup>4</sup>, -CONR<sup>3</sup>R<sup>4</sup>, -NHCOR<sup>3</sup>, -SO<sub>2</sub>R<sup>3</sup>, -SO<sub>2</sub>NHR<sup>3</sup>, -O(CH<sub>2</sub>)<sub>m</sub>NR<sup>3</sup>R<sup>4</sup>;

$R^3$  is selected from H or C<sub>1-4</sub> alkyl;

$R^4$  is selected from heterocyclyl or heteroaryl

$n$  is 0, 1, 2, 3, 4 or 5;

$m$  is 0, 1, 2 or 3;

$X$  and  $X'$ , which may be the same or different, are each selected from CH or N, provided that  $X$  and  $X'$  are not both N, and salts and solvates thereof.

2. (Original) A compound of formula (I) as claimed in claim 1, wherein  $R^1$  is positioned at the C(3) or C(6) position of the pyridine ring and is selected from H, halo, -CN, -CF<sub>3</sub>, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy.

International Application No. PCT/EP02/00991  
International Filing Date: 31 January 2002

3. (Original) A compound of formula (I) as claimed in claim 2, wherein  $R^1$  is H.

4. (Currently Amended) A compound of formula (I) as claimed in ~~any one of claims 1 to 3~~ claim 1, wherein  $R^2$  is  $-(CH_2)_n$ -phenyl, which may be further substituted by one or more substituents, which may be the same or different, selected from halo (such as fluoro, chloro, bromo),  $-CN$ ,  $-CF_3$ ,  $-OH$ ,  $-OCF_3$ ,  $C_{1-4}$  alkyl or  $C_{1-4}$  alkoxy,  $-NO_2$ ,  $-NH_2$ ,  $-NR^3R^4$ ,  $-CONR^3R^4$ ,  $-NHCOR^3$ ,  $-SO_2R^3$ ,  $-SO_2NHR^3$ ,  $-O(CH_2)_mNR^3R^4$ .

5. (Currently Amended) A compound of formula (I) as claimed in ~~any one of claims 1 to 4~~ claim 1 wherein n is 0 or 1.

6. (Original) A compound of formula (I) as claimed in claim 1 selected from:

[4-(2-Amino-4-pyridin-2-yl-thiazol-5-yl)-pyridin-2-yl]-phenyl-amine;

[4-(2-Amino-4-pyridin-2-yl-thiazol-5-yl)-pyridin-2-yl]-(4-methoxy-phenyl)-amine;

[4-(2-Amino-4-pyridin-2-yl-thiazol-5-yl)-pyridin-2-yl]-(4-fluoro-phenyl)-amine;

5-[4-(2-Amino-4-pyridin-2-yl-thiazol-5-yl)-pyridin-2-ylamino]-2-methoxy-phenol;

3-[4-(2-Amino-4-pyridin-2-yl-thiazol-5-yl)-pyridin-2-ylamino]-N-methyl-benzamide; and N-[4-(2-Amino-4-pyridin-2-yl-thiazol-5-yl)-pyridin-2-ylamino]-phenyl}-acetamide;

and salts and solvates thereof.

7. (Currently Amended) A pharmaceutical composition comprising at least one compound of formula (I) as claimed in ~~any one of claims 1 to 6~~ claim 1, together with a pharmaceutically acceptable diluent or carrier.


International Application No. PCT/EP02/00991  
 International Filing Date: 31 January 2002

8. (Currently Amended) A compound of formula (I) as claimed in ~~any one of claims 1 to 6~~ claim 1, for use as a medicament.

9. Cancelled.

10. (Currently Amended) A method for the treatment of a human or animal subject with a disorder characterised by the overexpression of TGF- $\beta$ , which method comprises administering to said human or animal subject an effective amount of a compound of formula (I) as claimed in ~~any one of claims 1 to 6~~ claim 1 or a physiologically acceptable salt or solvate thereof.

11. (Original) A process for the preparation of a compound of formula (I),



wherein,

$R^1$  is selected from H, halo, -CN, -CF<sub>3</sub>, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy;

$R^2$  is selected from -(CH<sub>2</sub>)<sub>n</sub>-phenyl, -(CH<sub>2</sub>)<sub>n</sub>-heterocyclyl, -(CH<sub>2</sub>)<sub>n</sub>-heteroaryl, of which may be further substituted by one or more substituents, which may be the same or different, selected from halo (such as fluoro, chloro, bromo), -CN, -CF<sub>3</sub>, -OH, -OCF<sub>3</sub>, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy, -NO<sub>2</sub>, -NH<sub>2</sub>, -NR<sup>3</sup>R<sup>4</sup>, -CONR<sup>3</sup>R<sup>4</sup>, -NHCOR<sup>3</sup>, -SO<sub>2</sub>R<sup>3</sup>, -SO<sub>2</sub>NHR<sup>3</sup>, -O(CH<sub>2</sub>)<sub>m</sub>NR<sup>3</sup>R<sup>4</sup>;

$R^3$  is selected from H or C<sub>1-4</sub> alkyl;

$R^4$  is selected from heterocyclyl or heteroaryl

$n$  is 0, 1, 2, 3, 4 or 5;

$m$  is 0, 1, 2 or 3;


$X$  and  $X'$ , which may be the same or different, are each selected from CH or N, provided that  $X$  and  $X'$  are not both N,

• and salts and solvates thereof,

International Application No. PCT/EP02/00991  
International Filing Date: 31 January 2002

which process comprises:

- a) treatment of a compound of formula (X) with an amine  $R^2NH_2$  in the presence of  $Pd_2(dba)_2$  and binap,



- b) subsequent removal of the protecting group from the resulting product.